Diffuse Large Cell Lymphoma clinical trials

Explore recruiting diffuse large cell lymphoma clinical trials.

Recruiting diffuse large cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Diffuse Large Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE)

Spain, Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine- Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL).

Poland, Spain, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial - NLG-LBC7 (POLAR BEAR)

Norway, Sweden, Denmark, Finland, Italy, Estonia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma

Spain, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Diffuse Large Cell Lymphoma trials by city

Diffuse Large Cell Lymphoma in Toronto Diffuse Large Cell Lymphoma in Vancouver Diffuse Large Cell Lymphoma in Montreal Diffuse Large Cell Lymphoma in Calgary Diffuse Large Cell Lymphoma in Edmonton Diffuse Large Cell Lymphoma in Ottawa Diffuse Large Cell Lymphoma in Winnipeg Diffuse Large Cell Lymphoma in Quebec City Diffuse Large Cell Lymphoma in Hamilton Diffuse Large Cell Lymphoma in Kitchener Diffuse Large Cell Lymphoma in London Diffuse Large Cell Lymphoma in Halifax Diffuse Large Cell Lymphoma in New York Diffuse Large Cell Lymphoma in Los Angeles Diffuse Large Cell Lymphoma in Chicago Diffuse Large Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease